Optimizing Aimovig Prior Authorization for Pulmonology Practices

While Aimovig (erenumab) is primarily prescribed for migraine prevention, pulmonology practices may encounter its prior authorization requirements due to patient comorbidities or integrated care models. Klivira streamlines the Aimovig prior authorization for pulmonology workflows, ensuring efficiency across all drug classes.

Revenue cycle directors and prior authorization coordinators in pulmonology face the complex task of managing diverse PA requirements, not only for respiratory-specific biologics but also for medications prescribed for co-occurring conditions. Understanding the nuances of Aimovig PA, even when not directly prescribed by a pulmonologist, is crucial for maintaining seamless patient care and optimizing administrative efficiency within the practice.

Aimovig (Erenumab) in the Broader Clinical Context

Aimovig, a CGRP receptor antagonist, is indicated for the preventive treatment of chronic and episodic migraine. While not a primary therapeutic agent in pulmonology, patients under a pulmonologist's care may have comorbidities requiring such medications. Managing these PAs efficiently is vital for a holistic patient experience and integrated care delivery.

Navigating Prior Authorization for Non-Pulmonary Drugs in a Pulmonology Setting

Pulmonology practices routinely manage complex prior authorizations for high-volume categories such as asthma biologics (e.g., Dupixent, Nucala), home oxygen, BiPAP, and IPF antifibrotics. However, administrative teams must also be equipped to handle PAs for medications like Aimovig, which, while outside the pulmonologist's direct prescribing scope, can still impact the practice's operational workflow if not managed effectively.

Key Prior Authorization Considerations for Aimovig

Initial prescription for preventive migraine therapy.
Step-therapy requirements, often necessitating trials of generic oral preventives.
Confirmation of chronic or episodic migraine diagnosis.
Patient-specific comorbidities that may influence payer policy.
Reauthorization following initial approval period.

Streamlining PA Workflows for All Medications with Klivira

Klivira's platform provides a unified solution for managing prior authorizations across all drug classes, including specialty medications like Aimovig. By automating data extraction from EMRs via SMART on FHIR and facilitating electronic submission through X12 278 or payer portals, Klivira reduces manual effort and accelerates approval times, regardless of the prescribing specialty.

Klivira's Impact on Pulmonology PA Efficiency

Beyond managing specific drug PAs, Klivira addresses the broader challenges faced by pulmonology practices. Our system integrates with clinical guidelines such as ATS, GOLD, and GINA, streamlining the documentation of eosinophil counts, prior controller therapy, and exacerbation history for high-volume asthma biologics. This comprehensive approach ensures that both specialty-specific and general drug PAs are handled with maximum efficiency.

Frequently asked questions

Why would a pulmonology practice encounter Aimovig prior authorizations?

Pulmonology practices may encounter Aimovig PAs when patients under their care are also being treated for migraines by other specialists. While not prescribed by the pulmonologist, the administrative team may still need to process or be aware of the PA as part of the patient's overall care record or if the practice uses a centralized PA system.

Does Klivira specifically automate Aimovig PAs?

Yes, Klivira's platform is designed to automate prior authorizations for a wide range of specialty medications, including Aimovig. Our system extracts necessary clinical data and submits requests electronically, reducing the manual burden for any drug requiring PA, irrespective of the clinical specialty.

How does Klivira help with step-therapy requirements common for Aimovig?

Klivira's platform incorporates intelligent logic to identify and document step-therapy compliance. For drugs like Aimovig, where trial-and-failure of generic preventives is often required, our system helps ensure all necessary documentation is present for submission, minimizing denial risks.

What are the typical documentation requirements for Aimovig PA?

Documentation for Aimovig PA typically includes confirmation of a migraine diagnosis (chronic or episodic), history of prior preventive treatments (especially trials of generic options), and patient response to previous therapies. Klivira helps consolidate and present this data effectively for submission.

Can Klivira integrate with our EMR to pull data for Aimovig PAs?

Yes, Klivira integrates with major EMR systems using standards like SMART on FHIR to securely pull relevant patient data. This capability streamlines the collection of clinical information needed for Aimovig and other prior authorization submissions, reducing manual chart review and improving data accuracy.